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O B J E C T I V E S In a cohort of patients with hereditary transthyretin-related amyloidosis (ATTR), we
aimed to assess the role of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) in
detecting myocardial amyloid inﬁltration across a wide spectrum of cardiac involvement and in
predicting major adverse cardiac events (MACE).
B A C KG ROUND Hereditary transthyretin-related amyloidosis is a challenging and underdiagnosed
condition where both early diagnosis and prognosis remain problematic.
METHOD S We evaluated 63 patients with ATTR: 40 with and 23 without echocardiographically
diagnosed amyloidotic cardiomyopathy (AC). Myocardial uptake of 99mTc-DPD scintigraphy was
semiquantitatively and visually assessed at 5 min and 3 h.
R E S U L T S All patients with AC showed moderate-to-severe myocardial tracer uptake (i.e., visual score
2). Within the subgroup without AC, only 4 patients (with Ala36Pro, Gly47Ala, Thr49Ala, and Glu89Gln
transthyretin mutations) showed myocardial tracer uptake and abnormal heart/whole body retention (H/WB)
values: in all these cases endomyocardial biopsies showed amyloidotic inﬁltration. The H/WB was positively
correlated with left ventricular (LV) mean wall thickness (Pearson’s r 0.695, p 0.001) and negatively with
LV ejection fraction (r  0.368, p  0.004). The H/WB was an unfavorable predictor of MACE-free survival
at Cox univariate analysis and contributed to the multivariate model. Notably, LV wall thickness 12 mm in
combination with H/WB 7.5 was associated with the highest event rate.
CONC L U S I O N S In ATTR, 99mTc-DPD scintigraphy can identify myocardial inﬁltration across a wide
spectrum of morphologic/functional cardiac involvement, allowing an early diagnosis of the disease
(even before the appearance of echocardiographic abnormalities). The 99mTc-DPD myocardial uptake is
a prognostic determinant of “cardiac” outcome in ATTR, either alone or in combination with LV wall
thickness. (J Am Coll Cardiol Img 2011;4:659–70) © 2011 by the American College of Cardiology
Foundation
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660ereditary transthyretin-related amyloidosis
(ATTR) is the most frequent form of fa-
milial systemic amyloidoses, a group of
severe diseases with neurological and poly-
isceral involvement (1–3). Hereditary trans-
hyretin-related amyloidosis is challenging and
idely underdiagnosed, because of an extreme phe-
otypic variability that ranges from almost exclusive
eurologic involvement to cases with a strictly
ardiologic presentation (1–3). Such heterogeneity
s mainly linked to specific transthyretin (TTR)
utations, geographic distribution, endemic/
onendemic type of aggregation (1–5). Echocar-
iography and electrocardiography (ECG) have an
stablished role in the diagnosis of overt forms of
amyloidotic cardiomyopathy (AC) (4–7).
Unfortunately, none of them gives infor-
mation with regard to the etiologic type of
amyloidosis; furthermore, their diagnostic
role in the early phases or in the mild
forms of the disease is limited by a low
specificity (4,5,7,8).
99mTc-3,3-diphosphono-1,2-propan-
odicarboxylic acid (99mTc-DPD) scintigra-
phy has proved to be useful in differential
diagnosis between TTR (both mutant and
wild-type) and immunoglobulin light-
chain (AL) etiologies in patients with
echocardiographically defined AC (9–11):
99mTc-DPD uptake is absent in unaffected
control subjects, strong in TTR-related
AC, and absent or weak in AL-derived
AC (10,11). However, apart from the
contribution in tissue diagnosis, the diag-
nostic possibilities of 99mTc-DPD in
ATTR have not yet been fully assessed. It
also remains to be determined whether
99mTc-DPD myocardial uptake has major
prognostic implications on cardiac events.
The present study was designed to evaluate the
diagnostic and prognostic contribution of 99mTc-
PD in ATTR across a wide spectrum of morpho-
ogic and functional cardiac involvement, including
arly stages of the disease.
M E T H O D S
Setting and study design. We enrolled all patients
iagnosed with ATTR who presented to our center
rom March 2004 to March 2010. In our referral
enter for the diagnosis and treatment of cardio-
yopathies, clinical examination, echocardio-
sy
arram, ECG, and 99mTc-DPD scintigraphy arepart of the usual diagnostic workup of patients
with suspected or confirmed cardiac amyloidosis.
Each patient was required to provide standard
informed consent for the execution of 99mTc-
DPD scintigraphy. Cardiac catheterization and
endomyocardial biopsy (EMB) were performed
in selected cases and in all potential candidates
for liver or combined liver/heart transplantation.
All patients provided informed consent for
anonymous publication of scientific data. Formal
ethical approval was not applicable for this ret-
rospective study involving only routinely per-
formed procedures.
Our study included a cross-sectional analysis of
baseline clinical and instrumental profiles and a
longitudinal analysis of ATTR patients to assess the
role of myocardial 99mTc-DPD uptake in predict-
ng major adverse cardiovascular events (MACE).
Diagnostic deﬁnitions. Diagnosis of systemic amy-
loidosis was based on histological documentation of
Congo-red staining and apple-green birefringence
under cross-polarized light in at least 1 involved
organ (12,13). The AC was echocardiographically
defined as end-diastolic thickness of the interven-
tricular septum 1.2 cm (in the absence of any
other plausible cause of ventricular hypertrophy)
(4,14). Other echocardiographic signs suggesting
cardiac amyloidosis were: granular sparkling ap-
pearance of ventricular myocardium, increased
thickness of right ventricular free wall, atrioventric-
ular valves or interatrial septum, and pericardial
effusion (4–6). Diagnosis of ATTR was defined by
a documented TTR mutation at deoxyribonucleic
acid analysis (15). Renal insufficiency was defined as
glomerular filtration rate 60 ml/min (14). The
assessment of peripheral nervous system involve-
ment was based on characteristic neurologic signs
and symptoms (typical symmetric ascending senso-
rimotor peripheral neuropathy) (14). Autonomic
impairment was defined by presence of orthostatic
hypotension, gastric-emptying disorder, pseudo-
obstruction, and voiding dysfunction not related to
direct organ infiltration (14).
Instrumental deﬁnitions. The ECG and echocardio-
raphic measures were based on standard defini-
ions (16,17). Left ventricular (LV) mass was cal-
ulated according to Devereux and was classified as
ncreased when 130 g/m2 in men and 110 g/m2
in women (18). The LV restrictive filling pattern
was defined in terms of E-wave deceleration time
150 ms accompanied by E/A-wave ratio 2.5 atA B B R E V I A T I O N S
A N D A C R O N YM S
99mTc-DPD 99mTc-3,3-
iphosphono-1,2-
ropanodicarboxylic acid
C amyloidotic
ardiomyopathy
L immunoglobulin
ight-chain
TTR hereditary
ransthyretin-related
myloidosis
CG electrocardiogram/
lectrocardiographic
MB endomyocardial biop
/WB heart/whole body
etention
V left ventricle/ventricul
ACEmajor adverse
ardiac events
OI region of interestpulsed Doppler echocardiography (19).
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661Histology and immunohistochemistry. Histological
ocumentation of amyloid deposition was obtained
ither in subcutaneous adipose tissue from abdom-
nal fat or from EMB. All myocardial samples
5 per patient) were microwave fixed/processed, and
ultiple 2-m sections were tested for presence of
amyloid by Congo-red staining and apple-green
birefringence under cross-polarized light micros-
copy. The amount of amyloid infiltration at EMB
was semiquantitatively classified as: mild (30% of
the analyzed tissue specimen), moderate (30% to
60% of the analyzed tissue specimen), or severe
(more than 60% of the analyzed tissue specimen).
Immunohistochemical analysis was performed by
the labeled Streptavidin-Biotin LSAB method with
an antibody against TTR (R.P. Linke, Max Planck
Institute of Biochemistry, Martinsried, Germany),
or by immunoelectron microscopy with specific
antibodies proteins (DAKO, Ely, United
Kingdom).
Scintigraphy protocol and image analysis. Patients
received 740 MBq of 99mTc-DPD intravenously; a
dual-head camera (ECAM, Siemens Medical Sys-
tems, Hoffman Estates, Illinois) equipped with
low-energy, high-resolution collimators was used.
Whole body scans were obtained 5 min (early) and
3 h (late) after injection. In patients showing cardiac
uptake, a myocardial single-photon emission com-
puted tomography study was acquired after the late
whole-body scan. Image analysis was independently
performed by experienced analysts unaware of all
patient data. Visual scoring of cardiac retention was
routine: score 0, absent cardiac uptake and normal
bone uptake; score 1, mild cardiac uptake, inferior
to bone uptake; score 2, moderate cardiac uptake
associated with attenuated bone uptake; or score 3,
strong cardiac uptake with mild/absent bone up-
take. Semiquantitative analysis of heart retention,
whole-body retention, and heart/whole body ratio
(H/WB) were evaluated from region-of-interest
(ROI) drawings in the standard manner. In brief,
rectangular ROIs were drawn over the heart, and
irregular ROIs were drawn over the kidneys and
bladder on anterior images. These ROIs were
copied and mirrored on posterior images, and geo-
metric means of the 2 projections were calculated
for each ROI. All ROIs were corrected for back-
ground counts. Total counts in the images were
considered as whole-body counts. Early whole-
body counts were used to represent the injected
activity. Whole-body retention was evaluated by
comparing counts in the late images (corrected for
decay and scan speed, and subtracting the activity in athe urinary tract and bladder) with the counts in the
early whole-body images. Heart retention was eval-
uated by comparing decay-corrected counts of the
heart in late images with counts in early whole-body
images. The H/WB ratios were calculated by di-
viding counts in the heart by counts in late whole-
body images.
Follow-up. Planning of follow-up visits was based
on clinical needs (or 6 monthly). Data collection
was closed in September 2010; for patients who had
not attended a visit in the previous 6 months, vital
status was ascertained by telephone and/or by con-
tacting referring physicians.
We defined MACE as the occurrence of death
from cardiovascular causes (due to either fatal ar-
rhythmias or severe worsening heart failure), hos-
pital stay due to congestive heart failure, complete
atrioventricular block, atrial fibrillation/flutter,
myocardial infarction, or stroke. Each prognostic
outcome was assessed by contacting the patients,
the family members, or the referring physician.
Statistical analysis. Summary statistics were ex-
ressed as median [interquartile range] or frequen-
ies (percentages). Independence of categorical
ariables was tested using Fisher exact test or
earson chi-square test. Continuous variables were
nalyzed using Mann-Whitney U test. Pearson
orrelation coefficient (r) was used to study the
ossible correlation of H/WB with mean LV wall
hickness and LV ejection fraction. MACE-free
urvival was analyzed with Kaplan-Meier curves.
atients were censored at time of solid organ
ransplantation. To explore possible associations
ith MACE-free survival, univariate Cox regres-
ion analysis was initially performed with clinical,
chocardiographic, ECG, and scintigraphic vari-
bles. Multivariate analysis was then performed by
ntering into the model the variables that were
ignificant (p  0.05) on univariate analysis but
nrelated to each other. A formal search for colin-
arity (with the variance inflation factor test) and
nteractions (with the test of proportional hazard
ssumption) was performed to guide the construc-
ion of the final statistical model. Analyses were
onducted with STATA (version 11.1 SE, Stata
orporation, College Station, Texas). Values of p 
.05 were considered significant.
R E S U L T S
Study population. A total of 63 patients with
TTR fulfilled the study protocol and entered thenalysis. Twenty-eight of these patients were in-
(
S
mylo
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662cluded in a previous study (11) analyzing the role of
99mTc-DPD scintigraphy in the differential diagno-
sis between AL and TTR-related AC. Fourteen
patients with ATTR evaluated during the same
period were excluded from this study due to lack of
informed consent or to a severe global clinical
Table 1. Clinical and Genetic Characteristics of Patients With AT
Overall Population
(n  63)
Age, yrs 53 (4166)
Male 39 (62)
NYHA functional class II 10 (16)
Neurologic/autonomic involvement 53 (84)
Carpal tunnel syndrome 17 (27)
TTR mutations
Val30Met 11 (17)
Ile68Leu 18 (29)
Thr49Ala 9 (14)
Glu89Gln 10 (16)
Other 15 (24)
Referral route
Cardiology 21 (33)
Neurology 27 (43)
Family screening 15 (24)
Disease duration, months 21 (353)
Glomerular ﬁltration rate, ml/min 77 (6494)
Values are n (%) or median (interquartile range).
AC  amyloidotic cardiomyopathy; ATTR  hereditary transthyretin-related a
Table 2. ECG and Echocardiographic Characteristics of Patients
of Echocardiographically Deﬁned AC
Overall Population
(n  63)
Abnormal ECG 49 (78)
Low QRS voltages 13/60 (22)
Atrial ﬁbrillation 4/62 (7)
Pacemaker 3/62 (5)
Prolonged P-R interval 12/60 (20%)
Left bundle branch block 1/60 (2)
Right bundle branch block 7/60 (12)
Left anterior hemiblock 22/60 (37)
Repolarization abnormalities 20/60 (33)
Indexed LV mass, g/m2 161 (118231)
Indexed LV mass/volume ratio 2.8 (2.14.4)
Interventricular septal thickness, mm 14 (1118)
LV mean wall thickness, mm 14 (1118)
LVEF, % 61 (5068)
LVEF 50% 16 (25)
E-wave deceleration time, ms 170 (142201)
Restrictive LV ﬁlling pattern 19 (30)
Mild pericardial effusion 30/61 (49)
Values are n (%) or median (interquartile range).
ECG  electrocardiographic; LV  left ventricular; LVEF  left ventricular ejectionimpairment (that was judged incompatible with the
execution of scintigraphy).
Distribution of TTR mutations was as follows:
Ile68Leu (n  18), Val30Met (n  11), Glu89Gln
n  10), Thr49Ala (n  9), Phe64Leu (n  3),
er23Asn (n  2), Ala36Pro (n  2), Arg34Thr
According to the Presence of Echocardiographically Deﬁned AC
Patients With AC
(n  40)
Patients Without AC
(n  23) p Value
57 (4867) 39 (3357) 0.001
31 (78) 8 (35) 0.002
10 (25) 0 (0) 0.024
30 (75) 23 (100) 0.024
14 (35) 3 (14) 0.111
0.234
4 (10) 7 (30)
14 (35) 4 (17)
5 (12) 4 (17)
7 (18) 3 (13)
10 (25) 5 (23)
0.001
21 (53) 0 (0)
18 (45) 9 (39)
1 (2) 14 (61)
30 (763) 7 (038) 0.050
74 (5892) 82 (7399) 0.125
idosis; NYHA  New York Heart Association; TTR  transthyretin.
h ATTR According to the Presence
Patients With AC
(n  40)
Patients Without AC
(n  23) p Value
40 (100) 5 (22) 0.001
11/38 (29) 0 (0) 0.140
4 (10) 0 (0) 0.293
3 (7) 0 (0) 0.545
10/39 (26) 2/21 (10) 0.185
1/38 (3) 0/22 (0) 0.999
6/38 (16) 1/22 (5) 0.408
19/38 (50) 2/22 (9) 0.003
19/38 (50) 1/22 (5) 0.001
194 (159256) 106 (89119) 0.001
3.9 (2.74.9) 1.8 (1.52.3) 0.001
16 (1420) 10 (911) 0.001
16 (1319) 10 (911) 0.001
53 (4865) 66 (6173) 0.001
15 (38) 0/23 (0) 0.002
160 (135215) 190 (160200) 0.296
17 (43) 0 (0) 0.001
28 (70) 0 (0) 0.001TRWitfraction; other abbreviations as in Table 1.
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663(n  2), Phe33Val (n  1), His88Arg (n  1),
hr59Lys (n  1), Ser50Arg (n  1), Gly47Ala
n  1), and Val14Leu (n  1), a novel TTR
Figure 1. Scintigraphic, Echocardiographic, and ECG Findings in
The patient with echocardiographically deﬁned cardiomyopathy (A)
boxylic acid uptake and very attenuated bone uptake. The patient
(B), carrying a non-Val30Met TTR mutation, shows a mild myocardia
ECG  electrocardiographic; TTR  transthyretin.utation not previously described. aAt baseline, 40 patients (63%) fulfilled the echo-
ardiographic diagnostic criteria of AC (14),
hereas 23 (37%) patients did not. In particular,
TR With and Without Cardiomyopathy
ws strong myocardial 99mTc-3,3-diphosphono-1,2-propanodicar-
normal echocardiographic and electrocardiographic assessment
cer uptake. ATTR  hereditary transthyretin-related amyloidosis;AT
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664fined cardiomyopathy, echocardiogram was normal
in 16 (69%) patients, whereas in 7 cases (31%) some
echocardiographic abnormalities were detectable:
interventricular septal thickness 12 mm in 3 cases
(13%), and increased interatrial septum thickness
(5 mm) in 2 cases (9%). Tables 1 and 2 summa-
ize the main clinical and instrumental (ECG/
chocardiographic) profiles of the patients. Patients
Comparison of 99mTc-DPD Heart/Whole Body Retention
ATTR Patients With and Without AC
ith (on the left) and without (on the right) amyloidotic cardiomyop-
The triangles represent patients with Val30Met transthyretin (TTR)
the dots represent patients with other than Val30Met TTR muta-
circles surrounding the dots in the upper right indicate the 4
ith other than Val30Met TTR mutation without cardiomyopathy but
igraphic myocardial tracer uptake. ATTR  hereditary transthyretin-
yloidosis; 99mTc-DPD  99mTc-3,3-diphosphono-1,2-propanodicar-
Table 3. Scintigraphic Findings in the Overall Population and Acc
Overall Population
(n  63)
Whole-body tracer retention (%)
Median 62.4
IQR 47.768.5
Heart tracer retention (%)
Median 5.3
IQR 2.37.8
Heart/whole body retention ratio
Median 7.5
IQR 4.110.6
Visual cardiac score
0
1
2
3
IQR  interquartile range; other abbreviations as in Table 1.e
id.ith AC were older than those without, with a
igher prevalence of male sex and a higher preva-
ence of TTR Ile68Leu mutation. The most repre-
ented mutation in patients without AC was the
al30Met. Only 43% of patients received the (final)
iagnosis of ATTR due to neurologic manifesta-
ions; the diagnostic route was cardiologic in 33%
nd related to family screening in 24%. Of note,
pproximately 40% of cases without AC showed
CG abnormalities (vs. 100% in the other group,
 0.001), most frequently consisting in nonspecific
repolarization abnormalities, first degree atrioven-
tricular block or QRS axis deviation.
Scintigraphic ﬁndings and scintigraphic-echocar-
diographic correlations. Figure 1 shows examples
illustrating the spectrum of 99mTc-DPD uptake
mong the groups under investigation, with the
orresponding echocardiographic and ECG images.
emiquantitative and visual scintigraphic findings
re summarized in Table 3 and Figure 2, in the
verall population and according to the presence of
ardiomyopathy. At semiquantitative analysis, heart
etention and H/WB were both higher in patients
ith cardiomyopathy. A visual myocardial uptake of
he scintigraphic tracer (i.e., visual score 1) was
resent in all patients with echocardiographically
efined cardiomyopathy. Within the subgroup
ithout cardiomyopathy, 19 patients (81%) did not
how any visible myocardial tracer uptake, whereas
patients (18%) showed myocardial tracer uptake
mild in 1 case, moderate in 2 cases, strong in 1
ase) and higher H/WB values (Fig. 2, Table 3). In
ll these 4 cases, LV wall thickness, left ventricular
ng to the Presence of an Echocardiographically Diagnosed AC
Patients With AC
(n  40)
Patients Without AC
(n  23) p Value
0.0001
65.6 41.5
57.974.0 37.857.8
0.0001
7.0 1.5
5.27.9 0.93.2
0.0001
10.0 3.1
7.411.3 2.05.0
0.0001
0 (0) 19 (81)
0 (0) 1 (5)
14 (35) 2 (9)
26 (65) 1 (5)Figure 2.
Between
Patients w
athy (AC).
mutation;
tions. The
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665profile were normal, whereas E/E= was abnormal in
1 case. The ECG showed nonspecific T-wave
abnormalities in 1 patient. All 4 cases carried
non-Val30Met TTR mutations (Thr49Ala, n  1;
Ala36Pro, n 1; Glu89Gln, n 1; Gly47Ala, n
1). As can be seen in Figure 3, in the overall
population, H/WB was positively correlated with
LV mean wall thickness (Pearson r  0.695, p 
0.001) and inversely correlated with LVEF (Pear-
son r  0.368, p  0.004).
Scintigraphic-histologic correlations. An EMB was
performed in 28 (70%) patients with echocardio-
graphically defines AC. Among patients without
AC, EMB was performed only in the 4 cases with
myocardial 99mTc-DPD tracer uptake (all candi-
ates for orthotopic liver transplantation) and
howed a mild-to-moderate amyloid infiltration in
ll cases. We did not find any correlation between
he extent of the histological infiltration at EMB
nd the degree of myocardial tracer uptake (p 
.86 at Kruskal-Wallis test) (Fig. 4).
Outcome and prognosis. The median duration of
ollow-up was 14 (6.2 to 32) months. No patients
ere lost to follow-up. Sixteen patients (25%) were
ubmitted to solid organ transplantation (liver
ransplantation, n  11; heart-liver transplantation,
 4; heart-liver-kidney transplantation, n  1).
ith regard to MACE, we recorded 15 total
vents: deaths from cardiovascular causes were re-
orded in 2 (3%) patients; hospital stay due to heart
ailure was recorded in 9 (14%) patients; complete
trioventricular block was recorded in 2 (3%) pa-
ients; new-onset atrial fibrillation/flutter was re-
orded in 1 (2%) patient; and sustained ventricular
achyarrhythmia was recorded in 1 (2%) case. An-
ualized rate of MACE was 0.121/year.
Figure 5 shows MACE-free survival in ATTR
atients according to (Fig. 5A) mean LV wall
Figure 3. Correlation Between H/WB and Mean LV Wall Thickne
Mean left ventricular (LV) wall thickness (left), and LV ejection (righ
with LV mean wall thickness and inversely correlated with LV ejectihickness ( or 12 mm), (Fig. 5B) H/WB ( or7.5, which represented the median value), and
Fig. 5C) the combination of the previous variables.
otably, the combination of LV wall thickness
12 and H/WB 7.5 was associated with the
ighest event rate (Fig. 5C).
Table 4 reports univariate and multivariate Cox
odels on MACE-free survival. At univariate anal-
sis, increasing age, left atrial diameter, mean LV
all thickness, and LV mass/volume ratio as well as
ncreasing New York Heart Association functional
lass at first evaluation, presence of low QRS
oltage, presence of restrictive filling pattern, and
ncreasing scintigraphic heart retention and H/WB
ere unfavorable predictors of MACE-free sur-
ival, whereas increasing LVEF was a favorable
nd LV Ejection at Pearson’s Correlation Test
he heart/whole body retention (H/WB) was positively correlated
raction.
Figure 4. Relation Between 99mTc-DPD H/WB Retention and
EMB Findings
No correlation was evident between the extent of the histologic inﬁltr
at endomyocardial biopsy (EMB) and the degree of myocardial tracer uss a
t). Tation
ptake(heart/whole body [H/WB] retention), p  0.864 at Kruskal-Wallis test.
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666predictor (a trend was also recorded for increasing
glomerular filtration rate). Therefore, we con-
structed 2 multivariate analysis models: the first one
included only significant and unrelated variables on
univariate analysis (i.e., age and filling pattern). The
second was obtained by forcing H/WB into the
previous one. Likelihood ratio chi-square was 24.13
in the first model and 20.10 in the second (likeli-
hood ratio test, p  0.044) (Table 4). No interac-
tions emerged between the variables included in the
models.
D I S C U S S I O N
Our study highlights the clinical relevance of
99mTc-DPD scintigraphy in the evaluation of
ATTR patients with assessed or suspected AC.
Indeed, our data provide 2 main findings: 1) in
patients with ATTR, 99mTc-DPD scintigraphy can
dentify myocardial infiltration across a wide spec-
rum of morphologic and functional cardiac in-
olvement, increasing the accuracy of echocardio-
raphic diagnosis of AC and allowing early
iagnosis of the disease; and 2) 99mTc-DPD myo-
cardial uptake is a prognostic determinant of “car-
diac” outcome in ATTR.
99mTc-DPD detection of myocardial involvement in
TTR. In clinical practice, scintigraphy has pro-
vided conflicting results in the diagnosis of cardiac
amyloidosis. 123I-labeled serum amyloid P (the
o-called “SAP”) protein binds in a calcium-
ependent way to all amyloid deposits, irrespective
f the protein of origin (20–22). Unfortunately, the
yocardium does not apparently uptake the tracer,
robably due to high background (blood) activity
nd decreased permeability of the cardiac tissue to
he tracer (9,20). 99mTc-aprotinin has been mainly
tudied in AL patients, in whom it accumulates in
arious organs, including the myocardium (23,24).
owever, available experience is limited, and quan-
itative assessment is not feasible (20,23–25). 123I-
metaiodobenzylguanidine does not bind directly to
amyloid deposits and has proved useful only in the
functional evaluation of amyloid cardiomyopathy,
because it indirectly reveals the impairment of
cardiac sympathetic nerve endings due to amyloid
deposition (20,26,27). Studies on bone tracers in
cardiac amyloidosis have produced conflicting re-
sults, with significant variations in diagnostic per-
formance (20,28–33). Our previous studies showed
that this variability was mainly related to the etiol-
ogy of amyloid deposits and that this characteristicFigure 5. MACE-Free Survival in ATTR Patients
Freedom from major adverse cardiac events (MACE) in patients with he-
reditary transthyretin-related amyloidosis (ATTR) according to (A) the
presence of increased thickness of left ventricular (LV) parietal wall (i.e., a
mean LV wall thickness 12 mm), (B) the median values of heart/whole
body retention (H/WB) ( 7.5), and (C) the combination of both variables
(in all cases, MACE-free survival was censored at time of solidcould be used for noninvasive differential diagnosis
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667between AL and TTR-related AC at least in cases
with intense or null tracer uptake (10,11).
In the present study, 99mTc-DPD was able to
isclose cardiac amyloidosis across a wide spectrum
f morphologic involvement, ranging from patients
ith overt cardiomyopathy to cases with normal
chocardiograms and normal or near-normal ECGs.
ur data suggest that the myocardial tracer uptake is
n expression of the extent of amyloidotic infiltra-
ion: amyloidosis was detected at myocardial histol-
gy in all cases with “positive” myocardial scintig-
aphy (visual score 0), and mean LV wall
hickness was linearly and positively correlated to
he cardiac tracer retention (Fig. 3). The absence of
significant correlation between the extent of amyloid
nfiltration at EMB and the degree of myocardial
racer uptake (Fig. 4) does not necessarily contrast
ith this interpretation, considering the intrinsic
spotty” nature of the EMB and the lack of a
uantitative morphometric evaluation of amyloid-
tic infiltration in our protocol.
Interestingly, 99mTc-DPD scintigraphy was pos-
itive in 4 cases with normal LV wall thickness and
circumferential function (diastolic longitudinal
function was slightly depressed in only 1 case). All
these patients were affected by TTR mutations
other than Val30Met. This finding is consistent
with the current knowledge that some non-Val30Met
TTR mutations are more aggressive in the develop-
Table 4. Univariate and Multivariate Analyses of Risk of MACE
Univariate
HR 95% C
Male 1.7 0.55
ATTR Val30Met vs. other mutations 0.3 0.042
Age (per yr) 1.1 1.01
Autonomic imbalance 1.9 0.75
Advanced neurosensorial stage 1.1 0.43
Disease duration (per month) 1.0 1.01
NYHA functional class at observation 8.8 2.03
Glomerular ﬁltration rate 0.9 0.91
Body mass index 0.9 0.81
Low QRS voltage on ECG 6.2 2.21
Left atrial diameter 1.1 1.01
Mean LV wall thickness (per mm) 1.3 1.11
LVEF 0.9 0.91
Indexed LV mass/volume ratio 1.5 1.22.
Pericardial effusion 5.7 1.620
LV restrictive ﬁlling pattern 3.6 1.39.
Heart retention 7.2 1.631
Heart/whole body retention ratio 7.2 1.632
CI  conﬁdence interval; HR  hazard ratio; MACE  major adverse cardiac evment and progression of myocardial involvement, meven in the absence of overt neurologic manifestations
or clear familial transmission.
The possibility of identifying myocardial involve-
ment before overt morphological abnormalities are
echocardiographically visible is potentially relevant
from a clinical perspective, particularly when con-
sidering that drugs that stabilize the tetramer and
possibly slow disease progression are starting to be
available (4,5,8). Diagnostic performance of 99mTc-
PD scintigraphy favorably compares with the
ther noninvasive techniques. With regard to
-dimensional echocardiography, data and diagnos-
ic criterion reported so far all refer to cases with
vert cardiomyopathy (14,34). Similar consider-
tions can be made with regard to standard ECG
4,35) and magnetic resonance (36). Tissue-
oppler and deformation imaging techniques have
roved to identify early impairment of LV mechan-
cs (37). However, these functional (all nonspecific)
bnormalities have been described mainly in pa-
ients with AL-amyloidosis (38) and are shared by
ther pathological conditions (such as hypertensive
eart disease). The possibilities offered by scintig-
aphy could usefully integrate with those of Doppler
chocardiography, increasing its specificity and
herefore its clinical usefulness. Furthermore, the
ntegration between echocardiography and scintig-
aphy could also be decisive in cases with echocar-
iographically overt cardiomyopathy. Indeed, it
e Overall Population With ATTR
alysis Multivariate Analysis
p Value HR 95% CI p Value
0.86
0.25
0.001 1.1 1.01.1 0.015
0.213
0.87
0.33
0.004
0.073
0.468
0.001
0.002
0.001
0.001
0.003
0.007
0.014 3.2 1.09.6 0.043
0.01
0.009 3.9 0.818.4 0.081
; other abbreviations as in Tables 1 and 2.in th
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I
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668in our series) patients present with an exclusively
cardiologic phenotype, typically with an LV hy-
pertrophy compatible with different interpreta-
tions ranging from hypertensive heart disease to
hypertrophic cardiomyopathy. This is the case of
some TTR mutations including Val122Ile (prob-
ably the most frequent TTR mutation, because
its prevalence is more than 4% in African Ameri-
cans), Leu111Met (the so called “FAC,” familial
AC, of Danish origin), Thr60Ala, and Ile68Leu.
The documentation of myocardial 99mTc-DPD
tracer uptake would be decisive in the diagnostic
workup of such cases.
Prognostic implication of 99mTc-DPD myocardial
uptake. This is the first study that investigates the
rognostic role of 99mTc-DPD in ATTR. The
atural history of ATTR is very difficult to assess
ue to the high genotypic heterogeneity and the
arity of the disease. These 2 factors explain the
aucity of large systematic studies of ATTR as a
hole. The vast majority of data with regard to
utcome and prognostic stratification of cardiac
myloidosis derive from studies of patients with AL
myloidosis (4,39,40). In this setting, the main
nown (negative) prognostic factors are advanced
ongestive heart failure, increased N-terminal pro–
-type natriuretic peptide, increased parietal thick-
ess, and trans-mitral restrictive filling pattern at
oppler evaluation (41). In general, groups of
atients with ATTR AC caused by non-Val30Met
utations tend to have a worse prognosis (com-
ared with Val30Met), even after liver transplanta-
ion (3,5,42). Because amyloidotic infiltration is
esponsible for the myocardial tracer uptake, it is
easonable to hypothesize that the amount of tracer
ptake could be a prognostic determinant of cardiac
vents. Our data seem to confirm this hypothesis:
/WB is not only a significant predictor of
ACE-free survival at Cox univariate analysis, but
t also interacts with the mean LV wall thickness in
redicting cardiovascular events: when mean LV
all thickness is 12 mm, a high myocardial tracer
ptake is associated with a particularly poor
ACE-free survival.
However, it should be noted that, in this rela-
ively small case series with a relatively low number
f events, only increasing age and the presence of
V restrictive filling pattern were independently as-
ociated with MACE-free survival. To correctly in-
erpret these prognostic data, it is necessary to consider
hat our series was mostly formed by patients withrevalence of cardiologic abnormalities even at first
valuation. The prognostic contribution could be
uite different in patients with Val30Met TTR
utation where myocardial involvement is infre-
uent (and age-dependent) and neurologic progres-
ion is generally the main prognostic determinant.
Study limitations. Although this study represents
the largest report of patients with ATTR ever
studied with myocardial scintigraphy, the relatively
small population (typical of a rare disease) might
represent an unavoidable limitation. In particular,
only 4 cases in our study showed myocardial tracer
uptake, despite normal echocardiography. So, the
statement that 99mTc-DPD scintigraphy can be
seful in the early diagnosis of ATTR-related
yocardial disease needs to be confirmed by further
tudies. In this retrospective study, where all the
xaminations were performed on the basis of a
linical indication, EMB was not performed when
chocardiogram and 99mTc-DPD scintigraphy were
both normal. Therefore, the study does not provide
information on the sensitivity of 99mTc-DPD scin-
tigraphy in this context.
B-type natriuretic peptide or N-terminal pro–
B-type natriuretic peptide collection (which was
not systematically performed in this study) could
have been usefully integrated with DPD uptake
data. Finally, it should be emphasized that the
clinical relevance of 99mTc-DPD might only
apply to ATTR patients and not to cases with AL
amyloidosis.
C O N C L U S I O N S
In patients with ATTR, 99mTc-DPD scintigra-
phy can identify myocardial infiltration across a
wide spectrum of morphologic and functional
cardiac involvement, increasing the accuracy of
the echocardiographic diagnosis of AC and al-
lowing an early diagnosis of the disease (even
before the appearance of echocardiographic ab-
normalities), at least in cases with non-Val30Met
TTR mutations. 99mTc-DPD myocardial uptake
is a prognostic determinant of “cardiac” outcome
in ATTR, either alone or in combination with
LV wall thickness.
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